Artiva Biotherapeutics Inc
NASDAQGM:ARTV
United States / Healthcare / Biotechnology
Exchange Data
Hide this widget
Price
4.44 USD
Day change
-0.62 (-12.25%)
52-week range
3.37 - 17.31
19:59 - Closed
After Hours4.52 +0.08 (+1.80%)
Summary of Artiva Biotherapeutics Inc
Hide this widget
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suff...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Year
10 Years
0.65 (17.15%)
Data Explorer
Hide this widget
Search metric that you want to observe. Create your own widget, customise and rearrange metrics
| Metric Name | Value | Trend |
|---|---|---|
| Dividend Yield | 0.0% | |
| P/E Ratio | -1.8x | |
| Revenue | 2.601 M | |
| Net Income to Company | -61.276 M |
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| ARTV | Peers | Sector | |
|---|---|---|---|
Market Cap | 107.8 M | 61.246 M | 66.063 M |
Price % of 52 Week High | 25.6% | 46.6% | 62.9% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -168.7% | -7.4% | -0.7% |
1 Year Price Total Return | -63.0% | -53.1% | -10.7% |
Beta (5 Year) | - | 1.03 | 0.64 |
In the News
Hide this widget
Fair Value
Hide this widget
Average
5.78
Upside
30.1%
Uncertainty
HIGH
Spread
3.13 - 9.14
Market Range
52 weeks
$3
$17
$4.44
Analyst Targets
5 analysts
$18
$23
$21
Investing Models
$3
$9
$5.78
Financial Health
Health Details
Hide this widget
Financial Health for Artiva Biotherapeutics is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Fair Performance
▼
▼
Financial Models for Artiva Biotherapeutics Inc
Model Gallery
Hide this widget
| 5Y DCF Revenue ExitView Updated 20 hours ago |
| 5Y DCF Growth ExitView Updated 20 hours ago |
| DuPont ROE AnalysisView Updated 7 days ago |
| 10Y Historical FinancialsView Updated 7 days ago |
| 5Y Historical FinancialsView Updated 7 days ago |
| EV / EBIT MultiplesView Updated 20 hours ago |
| EV / EBITDA MultiplesView Updated 20 hours ago |
| P/E MultiplesView Updated 20 hours ago |
| Price / Book MultiplesView Updated 20 hours ago |
| Price / Sales MultiplesView Updated 20 hours ago |
| EV / Revenue MultiplesView Updated 20 hours ago |
| CAPM WACC ModelView Updated 3 hours ago |
| 10Y DCF EBITDA ExitView Updated 20 hours ago |
| 10Y DCF Revenue ExitView Updated 20 hours ago |
| 10Y DCF Growth ExitView Updated 20 hours ago |
| 5Y DCF EBITDA ExitView Updated 20 hours ago |
| Earnings Power ValueView Updated 20 hours ago |
Historical Financials
Full Financials
Hide this widget
| (USD in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Sept-24 | Sept-23 | Sept-24 |
| Income Statement | |||||
| Revenue | 4.93 | 33 | 2.60 | 27 | 0.00 |
| Operating Income | (60) | (31) | (61) | 11 | (18) |
| Net Profit | (59) | (29) | (61) | 11 | (17) |
| Diluted EPS | -76.67 | -35.78 | -11.42 | 1.62 | -0.92 |
| EBITDA | (59) | (28) | (59) | 11 | (18) |
| Balance Sheet | |||||
| Cash & ST Invest. | 103 | 77 | 147 | 147 | |
| Current Assets | 105 | 80 | 151 | 151 | |
| Total Assets | 133 | 105 | 226 | 226 | |
| Current Liabilities | 26 | 12 | 13 | 13 | |
| Total Liabilities | 57 | 51 | 25 | 25 | |
| Total Equity | 76 | 54 | 201 | 201 | |
| Total Debt | 19 | 17 | 15 | 15 | |
| Cash Flow Statement | |||||
| Cash Flow Operations | (51) | (47) | (51) | (11) | (12) |
| Cash From Investing | (6.30) | (26) | (122) | (0.49) | (131) |
| Cash From Financing | (1.26) | 24 | 163 | 23 | 164 |
| Free Cash Flow | (57) | (51) | (52) | (11) | (12) |
Analyst Notes
March 20, 2025
Hide this widget